CD19 targeting of chronic lymphocytic leukemia with a novel Fc-domain–engineered monoclonal antibody

CD19 is a B cell–specific antigen expressed on chronic lymphocytic leukemia (CLL) cells but to date has not been effectively targeted with therapeutic monoclonal antibodies. XmAb5574 is a novel engineered anti-CD19 monoclonal antibody with a modified constant fragment (Fc)–domain designed to enhance...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Awan, Farrukh T., Lapalombella, Rosa, Trotta, Rossana, Butchar, Jonathan P., Yu, Bo, Benson, Don M., Roda, Julie M., Cheney, Carolyn, Mo, Xiaokui, Lehman, Amy, Jones, Jeffrey, Flynn, Joseph, Jarjoura, David, Desjarlais, John R., Tridandapani, Susheela, Caligiuri, Michael A., Muthusamy, Natarajan, Byrd, John C.
Format: Artigo
Idioma:Inglês
Publicat: American Society of Hematology 2010
Matèries:
Lymphoid Neoplasia
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC2826232/
https://ncbi.nlm.nih.gov/pubmed/19965644
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2009-06-229039
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars